Eli Lilly Options Trading: A Deep Dive into Market Sentiment

Whales with a lot of money to spend have taken a noticeably bearish stance on Eli Lilly.

Looking at options history for Eli Lilly LLY we detected 16 trades.

If we consider the specifics of each trade, it is accurate to state that 43% of the investors opened trades with bullish expectations and 56% with bearish.

From the overall spotted trades, 6 are puts, for a total amount of $200,214 and 10, calls, for a total amount of $442,590.

Get Started

Start Futures Trading Fast — with a $200 Bonus

Join Plus500 today and get up to $200 to start trading real futures. Practice with free paper trading, then jump into live markets with lightning-fast execution, low commissions, and full regulatory protection.

Get Started

Expected Price Movements

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $370.0 to $620.0 for Eli Lilly during the past quarter.

Volume & Open Interest Development

Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Eli Lilly's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Eli Lilly's substantial trades, within a strike price spectrum from $370.0 to $620.0 over the preceding 30 days.

Eli Lilly Call and Put Volume: 30-Day Overview

Significant Options Trades Detected:

About Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

In light of the recent options history for Eli Lilly, it's now appropriate to focus on the company itself. We aim to explore its current performance.

Current Position of Eli Lilly

• Trading volume stands at 852,221, with LLY's price down by 0.0%, positioned at $588.75.
• RSI indicators show the stock to be may be approaching overbought.
• Earnings announcement expected in 76 days.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Eli Lilly options trades with real-time alerts from Benzinga Pro.